Brief: Eiger BioPharmaceuticals Announces Leadership Change
15/12/2022 22:50
Dec 15 (Reuters) - Eiger BioPharmaceuticals Inc
EIGR.O :
* EIGER BIOPHARMACEUTICALS ANNOUNCES LEADERSHIP CHANGE
* EIGER BIOPHARMACEUTICALS INC - PRESIDENT AND CEO DAVID A.
CORY
RESIGNS FROM COMPANY EFFECTIVE IMMEDIATELY
* EIGER BIOPHARMACEUTICALS INC - DR. DAVID APELIAN NAMED
INTERIM
CEO
* EIGER BIOPHARMACEUTICALS INC - COMPANY PLANS TO INITIATE
AN
EXECUTIVE SEARCH TO IDENTIFY CANDIDATES TO SERVE AS A PERMANENT
CEO
Source text for Eikon: ID:nBw3sJ8VGa
Further company coverage: EIGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview